Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis-Reference-Cited by-同舟云学术

Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

Published:2017-05-26 Issue:5 Volume:14 Page:e1002309
ISSN:1549-1676
Container-title:PLOS Medicine
language:en
Short-container-title:PLoS Med

Author:

Snyder Alexandra^ORCID,Nathanson Tavi^ORCID,Funt Samuel A.,Ahuja Arun,Buros Novik Jacqueline^ORCID,Hellmann Matthew D.^ORCID,Chang Eliza^ORCID,Aksoy Bulent Arman^ORCID,Al-Ahmadie Hikmat,Yusko Erik,Vignali Marissa^ORCID,Benzeno Sharon,Boyd Mariel,Moran Meredith,Iyer Gopa,Robins Harlan S.^ORCID,Mardis Elaine R.,Merghoub Taha^ORCID,Hammerbacher Jeff^ORCID,Rosenberg Jonathan E.^ORCID,Bajorin Dean F.^ORCID

Funder

Ludwig Center for Cancer Research

National Cancer Institute

Publisher

Public Library of Science (PLoS)

Subject

General Medicine

Reference23 articles.

1. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer;T Powles;Nature,2014

2. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial;JE Rosenberg;Lancet,2016

3. Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanoma;MA Postow;Methods Mol Biol,2014

4. Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells;HS Robins;Blood,2009

5. IMGT®, the international ImMunoGeneTics information system® 25 years on;M-P Lefranc;Nucleic Acids Res,2015

Cited by 268 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrative analysis of pan-cancer single-cell data reveals a tumor ecosystem subtype predicting immunotherapy response;npj Precision Oncology;2024-09-15

2. RNA modification Regulators’ Co-Expression Score (RMRCoeS) predicts biochemical recurrence and therapy response in prostate cancer: A multi-omics and experimental validation study;International Immunopharmacology;2024-09

3. Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1/CCL5 mediated M1 macrophage polarization in melanoma;Biomaterials;2024-09

4. Immunotherapy shapes B-cell receptor repertoire to induce anti-tumor antibodies production in colon and lung cancer;Genome Instability & Disease;2024-08-27

5. A risk signature constructed by Tregs-related genes predict the clinical outcomes and immune therapeutic response in kidney cancer;2024-08-10